Jose Luis Tuon Fernandez

List of Publications by Citations

81 papers	5,723 citations	37 h-index	75 g-index
84 ext. papers	6,482 ext. citations	4.7 avg, IF	4.95 L-index

#	Paper	IF	Citations
81	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *European Heart Journal*, **2016**, 37, 2999-3058	23.5	1781
80	HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. *Journal of the American College of Cardiology*, **1998**, 32, 2057-64	15.1	349
79	Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. *Atherosclerosis*, **1999**, 147, 253-61	3.1	289
78	Anti-inflammatory and immunomodulatory effects of statins. *Kidney International*, **2003**, 63, 12-23	9.9	229
77	Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. *Circulation*, **2004**, 110, 2216-9	16.7	199
76	Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. *Thrombosis and Haemostasis*, **2017**, 117, 1296-1316	7	143
75	Novel methodologies for biomarker discovery in atherosclerosis. *European Heart Journal*, **2015**, 36, 2635-42	9.5	133
74	ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. *American Journal of Pathology*, **1998**, 153, 1825-37	5.8	118
73	Potential role of nuclear factor B in diabetic cardiomyopathy. *Mediators of Inflammation*, **2011**, 2011, 652097	4.3	109
72	Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. *Atherosclerosis*, **2002**, 160, 49-58	3.1	104
71	Proteomic analysis of human vessels: application to atherosclerotic plaques. *Proteomics*, **2003**, 3, 973-8	4.8	100
70	Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. *Cardiovascular Research*, **2009**, 81, 216-25	9.9	98
69	Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. *Stroke*, **2005**, 36, 1796-800	6.7	97
68	Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2009**, 297, H2109-19	5.2	79
67	Plasma fingerprinting with GC-MS in acute coronary syndrome. *Analytical and Bioanalytical Chemistry*, **2009**, 394, 1517-24	4.4	74
66	NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. *Stroke*, **2004**, 35, 458-63	6.7	74
65	Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. *Atherosclerosis*, **2006**, 187, 139-49	3.1	73

64	Quest for novel cardiovascular biomarkers by proteomic analysis. *Journal of Proteome Research*, **2005**, 4, 1181-91	5.6	72
63	Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. *International Journal of Endocrinology*, **2014**, 2014, 847827	2.7	66
62	Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. *PLoS ONE*, **2013**, 8, e78330	3.7	64
61	Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. *Journal of Proteome Research*, **2009**, 8, 5580-9	5.6	63
60	Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. *Journal of Cardiovascular Pharmacology*, **2006**, 47, 60-9	3.1	61
59	Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. *Cardiovascular Research*, **2003**, 57, 168-77	9.9	59
58	Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 320, 108-16	4.7	57
57	Phosphate: a stealthier killer than previously thought?. *Cardiovascular Pathology*, **2012**, 21, 372-81	3.8	53
56	Brugada-like electrocardiographic pattern in a patient with a mediastinal tumor. *PACE - Pacing and Clinical Electrophysiology*, **1999**, 22, 1264-6	1.6	52
55	Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. *American Journal of Cardiology*, **2014**, 113, 434-40	3	49
54	Updating experimental models of diabetic cardiomyopathy. *Journal of Diabetes Research*, **2015**, 2015, 656795	3.9	49
53	Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. *Cardiovascular Diabetology*, **2013**, 12, 172	8.7	48
52	Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. *Journal of Proteome Research*, **2007**, 6, 876-86	5.6	48
51	Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. *Survey of Ophthalmology*, **2009**, 54, 339-48	6.1	46
50	Alteration of energy substrates and ROS production in diabetic cardiomyopathy. *Mediators of Inflammation*, **2013**, 2013, 461967	4.3	44
49	Reference Values of Aortic Root in Male and Female White Elite Athletes According to Sport. *Circulation: Cardiovascular Imaging*, **2016**, 9,	3.9	41
48	Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. *European Journal of Pharmacology*, **2007**, 562, 119-29	5.3	40
47	Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. *American Journal of Cardiology*, **2008**, 102, 12-8	3	39

46	Vitamin D receptor activation and cardiovascular disease. *Nephrology Dialysis Transplantation*, **2012**, 27 Suppl 4, iv17-21	4.3	38
45	Targeting metabolic disturbance in the diabetic heart. *Cardiovascular Diabetology*, **2015**, 14, 17	8.7	37
44	Proteomic strategies in the search of new biomarkers in atherothrombosis. *Journal of the American College of Cardiology*, **2010**, 55, 2009-16	15.1	37
43	Regulation of matrix proteins and impact on vascular structure. *Current Hypertension Reports*, **2000**, 2, 106-13	4.7	37
42	Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. *PLoS ONE*, **2014**, 9, e95402	3.7	37
41	Biomarcadores en la medicina cardiovascular. *Revista Espanola De Cardiologia*, **2009**, 62, 677-688	1.5	35
40	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. *Cardiovascular Research*, **2019**, 115, 10-19	9.9	32
39	Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPAR□n the associated hypertrophy. *Journal of Proteomics*, **2012**, 75, 1816-29	3.9	29
38	Study of the capillary electrophoresis profile of intact □1-acid glycoprotein isoforms as a biomarker of atherothrombosis. *Analyst, The*, **2011**, 136, 816-22	5	28
37	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. *European Journal of Preventive Cardiology*, **2018**, 25, 948-955	3.9	27
36	Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. *Journal of Proteome Research*, **2011**, 10, 1374-82	5.6	26
35	HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. *Journal of Cardiovascular Pharmacology*, **2005**, 45, 468-75	3.1	24
34	Proteomic and metabolomic profiles in atherothrombotic vascular disease. *Current Atherosclerosis Reports*, **2010**, 12, 202-8	6	23
33	Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. *Proteomics*, **2009**, 9, 1982-93	4.8	22
32	Targeted and non-targeted metabolic time trajectory in plasma of patients after acute coronary syndrome. *Journal of Pharmaceutical and Biomedical Analysis*, **2011**, 56, 343-51	3.5	22
31	Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease. *Diabetes/Metabolism Research and Reviews*, **2016**, 32, 685-693	7.5	21
30	Assessment of chronic tricuspid regurgitation by colour Doppler echocardiography: a comparison with angiography in the catheterization room. *European Heart Journal*, **1994**, 15, 1074-84	9.5	19
29	Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. *PLoS ONE*, **2017**, 12, e0169826	3.7	18

28	Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease: a novel biomarker of endothelial function?. *Atherosclerosis*, **2008**, 201, 407-12	3.1	17
27	Patient-prosthesis mismatch in patients undergoing bioprosthetic aortic valve implantation increases risk of reoperation for structural valve deterioration. *Journal of Cardiac Surgery*, **2014**, 29, 439-44	1.3	15
26	Patients with neovascular age-related macular degeneration in Spain display a high cardiovascular risk. *European Journal of Ophthalmology*, **2012**, 22, 404-11	1.9	13
25	Proteomics in atherothrombosis: a future perspective. *Expert Review of Proteomics*, **2007**, 4, 249-60	4.2	13
24	Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. *Journal of Cardiology*, **2015**, 66, 22-7	3	12
23	The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables. *Cardiology*, **2015**, 132, 1-8	1.6	12
22	Proteomics in atherosclerosis. *Current Atherosclerosis Reports*, **2008**, 10, 209-15	6	11
21	Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. *Journal of Bone and Mineral Metabolism*, **2016**, 34, 587-98	2.9	10
20	Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, S189-93	12.7	10
19	Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. *Expert Review of Proteomics*, **2016**, 13, 857-71	4.2	9
18	Statin use in aortic aneurismal disease to prevent progression and cardiovascular events: review of experimental and clinical data C. *Current Vascular Pharmacology*, **2013**, 11, 299-304	3.3	9
17	Parathormone Levels Are Independently Associated with the Presence of Left Ventricular Hypertrophy in Patients with Coronary Artery Disease. *Journal of Nutrition, Health and Aging*, **2016**, 20, 659-64	5.2	8
16	Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology. *Cardiovascular Research*, **2018**, 114, 1411-1421	9.9	8
15	Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease. *PLoS ONE*, **2016**, 11, e0152816	3.7	8
14	Prolapsing right atrial myxoma evaluated by transesophageal echocardiography. *American Heart Journal*, **1991**, 122, 875-7	4.9	7
13	N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease. *PLoS ONE*, **2015**, 10, e0126741	3.7	6
12	Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial. *BMJ Open*, **2016**, 6, e011287	3	6
11	The proteomic approach in the development of prognostic biomarkers in atherothrombosis. *Recent Patents on Cardiovascular Drug Discovery*, **2009**, 4, 25-30		5

10	Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results. *Drugs*, **2004**, 64 Suppl 2, 61-7	12.1	5
9	Diagn□stico de amiloidosis cardiaca por lesiones cut□neas. *Revista Espanola De Cardiologia*, **2014**, 67, 666	1.5	3
8	Networks for improving care in patients with acute coronary syndrome: A framework. *Acute Cardiac Care*, **2014**, 16, 41-8		2
7	Diagnosis of cardiac amyloidosis by skin lesions. *Revista Espanola De Cardiologia (English Ed)*, **2014**, 67, 666	0.7	2
6	Inflammatory biomarkers and statins. *Drugs of Today*, **2005**, 41, 171-7		2
5	Nuevos mediadores implicados en la g□nesis de la aterosclerosis. *Cl□nica E Investigaci□n En Arteriosclerosis*, **2009**, 21, 25-33	1.4	1
4	Free-floating left atrial thrombus and its mechanical interaction with mitral regurgitant jet assessed by color Doppler echocardiography. *American Heart Journal*, **1992**, 123, 1067-9	4.9	1
3	Prote□mica cardiovascular: una nueva tecnolog□ para resolver viejos problemas. *Cl□nica E Investigaci□n En Arteriosclerosis*, **2011**, 23, 183-185	1.4	
2	[Not Available]. *Revista Espanola De Cardiologia*, **2009**, 62, 1342-3	1.5	
1	Efectos pleiotr□picos de telmisart□n en el paciente diab□tico. *Revista Espanola De Cardiologia Suplementos*, **2007**, 7, 23A-30A	0.2	